To investigate the underlying immunological mechanism that drove the enhanced therapeutic effect of 16 Gy + anti-CTLA4, tumor-draining lymph nodes (TDLNs) and spleens were excised after two cycles of IgG/anti-CTLA4 or one fraction of 16 Gy IR and two cycles of IgG/anti-CTLA4 (Figure S3a). The gene discussed is CTLA4; the disease is neoplasm.